Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore

Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore

Loading document ...
Page
of
Loading page ...

Author(s)

Author(s): Najeeb Ullah, Khurshid Ahmad Khan, Javeid Iqbal, Asim Rana, Bilal Bin Younis, Mohsin Asif, Aijaz Zeeshan Khan Chachar, Falak shan

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.2417 36 188 31-34 Volume 9 - Nov 2020

Abstract

Introduction: This Pandemic of Covid-19 has shaken the world and devastating and unpredictable nature of the disease and scenario becomes worse when we see limited treatment options for this disease. Objectives: The objective of the study was to assess the efficacy of Remdesivir in patients having early phase of the disease. Methodology: Study Settings: The study was conducted in two major tertiary care hospitals, Fatima Memorial Hospital, Bahria international Hospital, Lahore. Sample size & Sampling Technique: A total of 60 patients were selected for this study who were suffering from COVID 19, out of which 30 were given Remdesivir and 30 patients were kept in control group. Participants were enrolled in the study after fulfilling inclusion and exclusion criteria. It was Probability sampling. Study design: Non-randomized control interventional study. Data Analysis: Data was analyzed with respect to demographics and clinical characteristics. Outcome was observed in terms of recovery and death. Also, the oxygen requirement and respiratory rate was measured on presentation and on 14th day of admission. Furthermore, coexisting conditions such as diabetes, hypertension, ischemic heart disease and chronic kidney disease were also considered regarding outcome in case group and control group. Results: Mean age of the study participants was 53.2 with standard deviation (SD)±14.6 years, whereas average age of cases was 49.2±15.1 and control 57.1±13.1 years. Male were 60% of the patients and 40% were females, whereas both cases and control had 57% males. The most common co existing disease was hypertension which attributed to 53% of the total sample size followed by diabetes which was present in 47% of the study participants. 23 (38%) participants did not have any coexisting disease. The data did not show any promises with Remdesivir therapy in patients with or without ventilatory support in comparison with participants who did not receive Remdesivir.

Keywords

COVID 19, Pneumonia, Remdesivir

References

  1. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, et al.The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Journal of Clinical Medicine. 2020 Apr;9(4):1225. /doi.org/10.3390/jcm9041225
  2. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade R. The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. Available at SSRN 3582819. 2020 Apr 21.doi/org/10.2139/ssrn.3582819
  3. Rathore, J.S. and C. Ghosh, Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. Pathogens and disease, 2020. 78(6): p. ftaa042.doi.org/10.1093/femspd/ftaa042
  4. Cao, B., et al., A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 2020.doi.org/10.1056/nejmc2008043
  5. Brown, A.J., et al., Broad spectrum antiviral Remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral research, 2019. 169: p. 104541./doi.org/10.1016/j.antiviral.2019.104541.
  6. Agostini, M.L., et al., Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 2018. 9(2).doi.org/10.1128/mbio.00221-18
  7. Madsen, L.W., Remdesivir for the Treatment of Covid-19-Final Report. The New England Journal of Medicine, 2020.doi.org/10.1056/nejmc2022236
  8. Beigel, J.H., et al., Remdesivir for the treatment of Covid-19—preliminary report. The New England journal of medicine, 2020.doi.org/10.1056/nejmc2022236
  9. Wang, Y., et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 2020.doi.org/10.1016/s0140-6736(20)31022-9
  10. Goldman, J.D., et al., Remdesivir for 5 or 10 days in patients with severe Covid-19. New England Journal of Medicine, 2020.doi.org/10.1056/nejmc2022236
  11. Adamsick, M.L., et al., Remdesivir in patients with acute or chronic kidney disease and COVID-19. Journal of the American Society of Nephrology, 2020. 31(7): p. 1384-1386./doi.org/10.1681/asn.2020050589

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue April 2021

Volume 10, April 2021


Table of Contents



World-wide Delivery is FREE

Share this Issue with Friends:


Submit your Paper